Abbott Laboratories (Pakistan) Limited manufactures, imports, and markets generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products in Pakistan, Afghanistan, Sri Lanka, Bangladesh, and Switzerland. It operates through Pharmaceutical, Nutritional, Diagnostics, and Others segments. The company engages in the manufacturing, importing, and marketing of branded generic pharmaceutical products; AND import and marketing of nutritional products. It imports and markets diagnostic equipment, molecular devices, and testing kits; and manufactures and markets diabetes care and general healthcare products. The company offers its products under the Brufen, Surbex Z, Duphaston, Arinac, Ensure, Pediasure, Glucerna, FreeStyle Libre, and Alinity brand names. It exports its products. The company was founded in 1888 and is based in Karachi, Pakistan. Abbott Laboratories (Pakistan) Limited operates as a subsidiary of Abbott Asia Investments Limited.
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Over the last 7 days, the market has dropped 2.4%, driven by declines in the Financials and Energy sectors of 3.1% and 3.8%, respectively. In contrast, the Communication Services sector has actually gained 15%. In the last year, the market is actually up 69%. Earnings are forecast to grow by 11% annually. Market details ›